Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins

Junru Wang; Huaien Zheng; Xiaohua Qiu; Ashwini Kulkarni; Louis M. Fink; Martin Hauer-Jensen

doi:10.1160/TH05-05-0330

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(05): 1054-1059
DOI: 10.1160/TH05-05-0330

Wound Healing and Inflammation/Infection

Schattauer GmbH

Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins

Authors

Junru Wang

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA
Huaien Zheng

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA
Xiaohua Qiu

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA
Ashwini Kulkarni

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA
Louis M. Fink

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA

²Central Arkansas Veterans Healthcare System, Little Rock, Arizona, USA
Martin Hauer-Jensen

¹University of Arkansas for Medical Sciences, Little Rock, Arizona, USA

²Central Arkansas Veterans Healthcare System, Little Rock, Arizona, USA

Abstract

Summary

Endothelial dysfunction is involved in radiation responses in many normal tissues, including intestine. Endothelium-directed interventions ameliorate intestinal radiation injury (radiation enteropathy) in animal models, and anecdotal reports also suggest a beneficial effect of heparin. This study assessed low molecular weight heparin as an intestinal radiation response modifier. Rats underwent localized small bowel irradiation. Groups of rats were treated with saline, nadroparin (3 mg/kg/d), or a nonanticoagulant heparin (SR80258, 3 mg/kg/d), from 3 days before to 2 weeks after irradiation. The intestinal radiation response was assessed 2 weeks and 6 weeks after irradiation using quantitative histology; morphometry, and cellular and molecular endpoints. Compared to vehicle-treated controls, nadroparin sig-nificantly exacerbated structural radiation injury, neutrophil infiltration, and TGFβ and collagen I immunoreactivity levels 2 weeks after irradiation. SR80258 was associated with increased TGFβ levels, but the other parameters did not reach statistical significance. At 6 weeks, structural, cellular, and molecular injury was similar in the three experimental groups. Heparin, in contrast to antiplatelet agents and direct thrombin inhibitors, does not ameliorate, but exacerbates acute intestinal radiation toxicity. These data underscore the importance of heparin as an inhibitor of physiological anti-inflammatory mechanisms during tissue injury, as well as the non-anticoagulant effects of heparin. Moreover, these data may have implications for the use of heparin during radiation therapy.

Keywords

Endothelium - intestine - radiation injuries - heparin

Full Text

References

References
1 Denham JW. et al. The radiotherapeutic injury – a complex “wound”. Radiother Oncol 2002; 63: 129-45.
2 Wang J. et al. Deficiency of microvascular thrombomodulin and upregulation of protease-activated receptor 1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis. Am J Pathol 2002; 160: 2063-72.
3 Ward WF, Molteni A, Ts’ao C. Endothelial-oriented strategies to spare normal tissues. The Radiation Biology of the Vascular Endothelium.. Rubin DB. Boca Raton: CRC Press; 1998: 185-208.
4 Wang J. et al. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation- induced toxicity in rat small intestine. Thromb Haemost 2002; 87: 122-8.
5 Wang J. et al. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side effects after radiation therapy and as countermeasure against radiation exposure. J Thromb Haemost 2004; 2: 2027-35.
6 Boys F. et al. The effect of heparinization on experimental post-irradiation tissue changes in the lung. Am J Roentgenol Radium Ther 1943; 50: 1-8.
7 Fleming WH. et al. The effect of gamma radiation on the fibrinolytic system of dog lung and its modification by certain drugs: relationship to radiation pneumonitis and hyaline membrane formation in lung. J Nucl Med 1962; 3: 341-51.
8 Hauer-Jensen M. et al. Effects of accelerated fractionation on radiation injury of the small intestine: A new rat model. Int J Radiat Oncol Biol Phys 1988; 14: 1205-12.
9 Richter KK. et al. Association of transforming growth factor β immunoreactivity with specific histopathologic lesions in subacute and chronic experimental radiation enteropathy. Radiother Oncol 1996; 39: 201-302.
10 Hauer-Jensen M. et al. Localized subclinical radiation enteropathy prolongs intestinal transit time. An experimental study in a rat model. Radiat Oncol Invest 1995; 3: 157-66.
11 Campo C. et al. Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses. J Appl Physiol 1999; 86: 549-57.
12 Mutoh S. et al. Heparin increases cell membrane-associated heparan sulfate proteoglycan in balloon-injured rat carotid artery. J Vasc Res 1993; 30: 161-8.
13 Herbert J-M. et al. Protein kinase C α expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo . J Biol Chem 1996; 271: 25928-35.
14 Langberg CW. et al. Tolerance of rat small intestine to localized single dose and fractionated irradiation. Acta Oncol 1992; 31: 781-7.
15 Langberg CW. et al. Significance of overall treatment time for the development of radiation-induced intestinal complications. An experimental study in the rat. Cancer 1994; 73: 2663-8.
16 Hauer-Jensen M. et al. Late changes following single dose roentgen irradiation of rat small intestine. Acta Radiol Oncol 1983; 22: 299-303.
17 Baddeley AJ. et al. Estimation of surface area from vertical sections. J Microsc 1986; 142: 259-76.
18 Langberg CW. et al. Relationship between intestinal fibrosis and histopathologic and morphometric changes in consequential and late radiation enteropathy. Acta Oncol 1996; 35: 81-7.
19 Wang J. et al. Influence of short-term octreotide administration on chronic tissue injury, transforming growth factor β (TGF-β) overexpression, and collagen accumulation in irradiated rat intestine. J Pharmacol Exp Ther 2001; 297: 35-42.
20 PE Applied Biosystems. Relative quantitation of gene expression.. Norwalk, CT: Perkin-Elmer Corp.; 2001
21 Boughton-Smith NK. et al. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions 1988; 25: 115-23.
22 Pulletz S. et al. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000; 28: 2881-6.
23 Hoffmann JN. et al. Adverse effect of heparin on antithrombotic action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88: 242-52.
24 De Cristofaro R. et al. Effect of high- and low-molecular- weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation 1998; 98: 1297-301.
25 Hauer-Jensen M. et al. Radiation injury and the protein C pathway. Crit Care Med 2004; 32: S325-S330.
26 Lagunoff D. et al. Mast cell granule heparin proteoglycan induces lacunae in confluent endothelial cell monolayers. Am J Pathol 1999; 154: 1591-600.
27 Brunnee T. et al. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 1997; 27: 653-63.
28 Imaizumi T. et al. Heparin induces fibroblast proliferation, cell-matrix interaction and epidermal growth inihibition. Exp Dermatol 1996; 5: 89-95.
29 Tajima S. et al. Post-translational regulation of type I collagen synthesis by heparin in vascular smooth muscle cells. J Biochem 1995; 117: 353-8.
30 Kenagy RD. et al. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994; 93: 1987-93.
31 Mummery RS. et al. Characterization of the heparin- binding properties of IL-6. J Immunol 2000; 165: 5671-9.
32 Gospodarowicz D. et al. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475-84.
33 Zheng H. et al. Recombinant soluble transforming growth factor-β type II receptor ameliorates radiation enteropathy in the mouse. Gastroenterology 2000; 119: 1286-96.
34 McCaffrey TA. et al. Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α 2-macroglobulin inactive complex. J Cell Biol 1989; 109: 441-8.
35 Lyon M. et al. The interaction of the transforming growth factor-βs with heparin/heparin sulfate is isoform- specific. J Biol Chem 1997; 272: 18000-6.
36 Lindstedt L. et al. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis 2001; 155: 87-97.
37 Caughey GH. et al. Angiotensin II generation by mast cell α- and β-chymases. Biochim Biophys Acta 2000; 1480: 245-57.
38 Cohen EP. et al. The renin-angiotensin system in experimental radiation nephropathy. J Lab Clin Med 2002; 138: 251-7.
39 Wolf G. et al. Angiotensin II stimulates expression of transforming growth factor β receptor type II in mouse proximal tubular cells. J Mol Med 1999; 77: 556-64.
40 Hallgren J. et al. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 2001; 40: 7342-79.
41 Wang J. et al. Upregulation and activation of proteinase- activated receptor-2 in early and delayed radiation injury in the rat intestine: influence of biological PAR-2 activators. Radiat Res 2003; 160: 524-35.